课题基金 / 基金详情

IGF::OT::IGF VADIS TRIAL: PHASE II TRIAL OF E75 PEPTIDE VACCINE IN WOMEN WITH DCIS OF THE BREAST

IGF::OT::IGF VADIS TRIAL: PHASE II TRIAL OF E75 PEPTIDE VACCINE IN WOMEN WITH DCIS OF THE BREAST
IGF::OT::IGF VADIS 试验：E75 肽疫苗用于患有乳腺癌的女性的 II 期试验
批准号：
10017779
负责人：
POWEL BROWN
金额：
$5.82万
依托单位：
UNIVERSITY OF TX MD ANDERSON CAN CTR
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
项目状态：
已结题
起止时间：
2015-09-15 至 2020-09-14
来源：
https://reporter.nih.gov/project-details/10017779
关键词：
Activities of Daily LivingAdverse eventApoptosisBiological AssayBiopsyBreastCASP3 geneCD3 AntigensCD8-Positive T-LymphocytesCD8B1 geneCell ProliferationCellsCleaved cellClinical TrialsCytotoxic T-LymphocytesERBB2 geneEligibility DeterminationEpitope spreadingExcisionFrequenciesGranulocyte-Macrophage Colony-Stimulating FactorHLA-A2 AntigenHistologicImmune responseImmunohistochemistryInfiltrationLymphocyteMulticenter StudiesNoninfiltrating Intraductal CarcinomaOperative Surgical ProceduresParticipantPatientsPeptide VaccinesPhaseRandomizedSlideSpecimenStainsT cell responseToxic effectTumor AntigensVaccinatedVaccinationVaccinesWomanarmcytokineimmunogenicityphase II trialresponse

项目摘要

项目成果

POWEL BROWN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The proposed clinical trial will evaluate immunogenicity of E75 peptide vaccine in women with ductal carcinoma in situ in comparison to GM-CSF alone. It is a pre-surgical/ post-surgical phase IIb, randomized, multi-center study for women with histologically confirm ductal carcinoma in situ. HLA-A2+ participants who meet all other eligibility criteria will be randomized to receive NeuVaxTM (nelipepimut-S; 1000 μg of E75 and 250 μg of GM-CSF) or GM-CSF alone. Patients randomized to the nelipepimut-S + GM-CSF arm will receive three vaccinations of nelipepimut-S (1000 μg) and GM-CSF (250 μg) administered intradermally two weeks apart prior to surgery, and three vaccinations 1 month apart post surgery for six total vaccinations.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE BIOMARKERS; TASK ORDER: PREVENTION OF COLORECTAL CANCER WITH IPSC-
TASK ORDER: PRECLINICAL TESTING OF CD73 INHIBITORS FOR PANCREATIC CANCER IMMUNOPREVENTION
TASK ORDER: PRECLINICAL TESTING OF CD73 INHIBITORS FOR PANCREATIC CANCER IMMUNOPREVENTION
OTHER FUNCTIONS - CANCER PREVENTION AGENT DEVELOPMENT PROGRAM: EARLY PHASE CLINICAL RESEARCH
海外基金